Geron, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $4.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gil Blum has given his Buy rating due to a combination of factors that balance softer near‑term guidance with improving capital efficiency and future catalysts. While Geron’s 2026 revenue outlook for Rytelo came in below both his and the Street’s prior expectations, he still anticipates healthy double‑digit year‑over‑year growth and has modestly reduced his sales forecast to reflect the new guidance. The company’s decision to narrow operating expense targets following recent workforce reductions supports a leaner cost structure and extends the cash runway, which Blum views as a strategic positive rather than purely defensive.
In his view, the push toward tighter spending and capital discipline positions Geron to achieve cash flow breakeven in 2027, improving the long‑term investment case despite near‑term forecast revisions. Beyond Rytelo, Blum highlights the upcoming interim readout from the ImpactMF trial of imetelstat in myelofibrosis in the second half of 2026 as a potential value driver that is not fully reflected in current expectations. Taken together, he sees a favorable risk‑reward profile, with disciplined cost management, a credible path to profitability, and meaningful clinical milestones ahead supporting his Buy rating and $4 price target.
Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Cartesian Therapeutics, and TScan Therapeutics. According to TipRanks, Blum has an average return of 7.8% and a 40.32% success rate on recommended stocks.
In another report released yesterday, TipRanks – Google also upgraded the stock to a Buy with a $1.50 price target.